Please see abstract below and accompanying link.
After at least 90 years of hard work and unfulfilled anticipation for a malaria vaccine, could this be finally it? Is there really light at the end of the tunnel now? We welcome perspectives and thoughts on this time-honoured challenge.
Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults
Caroline Ogwang,1* Domtila Kimani,1* Nick J. Edwards,2,3 Rachel Roberts,2,3 Jedidah Mwacharo,1 Georgina Bowyer,3 Carly Bliss,3 Susanne H. Hodgson,2,3 Patricia Njuguna,1 Nicola K. Viebig,4 Alfredo Nicosia,5,6,7 Evelyn Gitau,1 Sandy Douglas,2,3 Joe Illingworth,3 Kevin Marsh,1,2
Alison Lawrie,2 Egeruan B. Imoukhuede,2,4 Katie Ewer,3 Britta C. Urban,8* Adrian V. S. Hill,2,3* Philip Bejon,1,2*† the MVVC group9
Protective immunity to the liver stage of the malaria parasite can be conferred by vaccine-induced T cells, but no subunit vaccination approach based on cellular immunity has shown efficacy in field studies. We randomly allocated 121 healthy adult male volunteers in Kilifi, Kenya, to vaccination with the recombinant viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia Ankara (MVA), both encoding the malaria peptide sequence ME-TRAP (the multiple epitope string and thrombospondin-related adhesion protein), or to vaccination with rabies vaccine as a control. We gave antimalarials to clear parasitemia and conducted PCR (polymerase chain reaction) analysis on blood samples three times a week to identify infection with the malaria parasite Plasmodium falciparum. On Cox regression, vaccination reduced the risk of infection by 67% [95% confidence interval (CI), 33 to 83%; P = 0.002] during 8 weeks of monitoring. T cell responses to TRAP peptides 21 to 30 were significantly associated with protection (hazard ratio,0.24; 95% CI, 0.08 to 0.75; P = 0.016).
Link leads to: http://www.medicalnewstoday.com/articles/293639.php